Aclaris Therapeutics, Inc. Stock Split Ratio
Aclaris Therapeutics, Inc. (ACRS) reported Stock Split Ratio of 28.99% for the 1-month period ending 2015-09-30, per its 10-K filed 2018-03-12.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2018-03-12
- 2015-09-30: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 28.99%.
- 2015-09-24: Stockholders' Equity Note, Stock Split, Conversion Ratio 28.99%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month |
|---|---|---|
| 2015-09-30 | 28.99% 10-K · filed 2018-03-12 | |
| 2015-09-24 | 28.99% 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |